Eli Casdin - 18 Jun 2026 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: LAB
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 17:41:32 UTC
Prior SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Eli Casdin

Key filing fact

Eli Casdin filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 23 Jun 2026.

Key facts

This page summarizes Eli Casdin's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 17:41.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001534264 Primary reporting owner

Casdin Eli

Relationship: Director, 10%+ Owner
Address: C/O STANDARD BIOTOOLS INC., 50 MILK STREET, 10TH FLOOR, BOSTON
Signature: /s/ Eli Casdin
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Award

Transaction value
Shares: +99,116
Change %: +3.4%
Price: $0.000000^*
Shares after: 3,053,169
Date: 18 Jun 2026
Ownership: Direct
Footnotes: F1

LAB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,939,637
Date: 18 Jun 2026
Ownership: Casdin Private Growth Equity Fund II, L.P.
Footnotes: F2

LAB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,744,219
Date: 18 Jun 2026
Ownership: By Casdin Private Growth Equity Fund, L.P.
Footnotes: F3

LAB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 72,100,000
Date: 18 Jun 2026
Ownership: Casdin Partners Master Fund, L.P.
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LAB transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +175,923
Change %
Price: $0.000000^*
Shares after: 175,923
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 175,923
Exercise price: $0.8297
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

Footnote F2

The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

Footnote F3

The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

Footnote F4

The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

Footnote F5

The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

SEC remarks

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.